Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study

Table 2 Edoxaban interruption by EHRA bleeding risk level and time of interruption relative to surgery

	Pre- and postprocedure	Preprocedure only	Postprocedure only	No interruption	Total
Major surgery^{a, b}	160 (58.4)	47 (17.2)	13 (4.7)	54 (19.7)	274 (100)
Nonmajor surgery^c	114 (22.3)	222 (43.4)	16 (3.1)	160 (31.3)	512 (100)
High risk	6 (46.2)	4 (30.8)	0	3 (23.1)	13 (100)
Low risk	38 (20.3)	70 (37.4)	6 (3.2)	73 (39.0)	187 (100)
Minor risk	69 (22.2)	148 (47.6)	10 (3.2)	84 (27.0)	311 (100)
Unknown	1 (100)	0	0	0	1 (100)

Data are shown as n (%)^d
High-risk nonmajor surgeries include orthopaedic (hand surgery; n = 4), gastroenterology (tumour excision; n = 5); cardiothoracic and vascular (thoracotomy/thoracocentesis ± chest tubes; n = 3), and general surgery (solid organ resection; n = 1)
EHRA European Heart Rhythm Association, n Number of surgeries
^aMedian edoxaban interruption time for major surgeries was 4.0 days
^bFor 2 surgeries, data for edoxaban use on the date of the surgery are unavailable
^cMedian edoxaban interruption time for nonmajor surgeries was 1.0 day
^dPercentages are relative to the total number of surgeries in each surgery group

ISSN: 1477-9560